SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

Background: Despite (neo) adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate, some patients with primary osteosarcoma progress during first-line systemic treatment and have a poor prognosis. In this study, we investigated whether patients with early disease progression (EDP), are cha...

Full description

Bibliographic Details
Main Authors: Evelien G. E. Hurkmans, Jan B. Koenderink, Jeroen J. M. W. van den Heuvel, Yvonne M. H. Versleijen-Jonkers, Melissa H. S. Hillebrandt-Roeffen, Johanne M. Groothuismink, Hanneke I. Vos, Winette T. A. van der Graaf, Uta Flucke, Grigor Muradjan, Hendrik W. B. Schreuder, Melanie M. Hagleitner, Han G. Brunner, Hans Gelderblom, Anne-Marie Cleton-Jansen, Henk-Jan Guchelaar, Eveline S. J. M. de Bont, Daan J. Touw, G. Jan Nijhoff, Leontien C. M. Kremer, Huib Caron, Rachael Windsor, Ana Patiño-García, Anna González-Neira, Federica Saletta, Geoff McCowage, Sumanth Nagabushan, Daniel Catchpoole, D. Maroeska W. M. te Loo, Marieke J. H. Coenen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
osteosarcoma
pharmacogenetics
doxorubicin
L-type amino acid transporter 2
early disease progression
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1042989/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1042989/full

Similar Items